fda warning letters glp-1 september 2025 Last month, the issued 25 to telehealth companies over what it called false or misleading claims about compounded medications. Read more at the link in the comments below FDA Issues Warning Letters to

What Emerging Research Says GLP-1 Medications May Do to Your Bones - The Studies Your Doctor May Not Have Read Yet Quick Answer: Emerging research from 2024-2025 suggests GLP-1 receptor agonist medications may be associated with bone density changes in specific populations, primarily driven by rapid weight loss rather than a confirmed direct drug effect on bone cells

HCPCS J-codes for biologics are reported by unit (e.g., J1745 = per 10 mg infliximab)

Dietary choline deficiency causes DNA strand breaks and alters epigenetic marks on DNA and histones

doi: 10.1080/14786419.2010.535159 157 MagnaniMCastro-GomezRJHMoriMPKuasneHGregrioEPLibosFet al